GlassScriptPhysician profile
Mitika T Maddula
NPI 1225263197
$6,563.21
in general payments reported to CMS, 2019-2025
30 companies · $2,571 in 2025
The $2,571 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $374 · 2021: $147 · 2022: $327 · 2023: $1,232 · 2024: $828 · 2025: $2,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,630.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,234.50 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $985.63 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $685.68 | 2019-2025 | Lifevest |
| Pfizer INC. | $530.33 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $513.73 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $402.93 | 2024-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $353.43 | 2019-2025 | |
| Amgen INC. | $254.73 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $242.31 | 2019-2025 | Farxiga |
| Scpharmaceuticals INC. | $159.46 | 2023-2025 | |
| Medtronic, INC. | $143.30 | 2021-2024 | Micra, Linq II, Aurora Ev-Icd Mri Surescan |
| Silk Road Medical, INC. | $125.00 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $124.44 | 2019-2025 | Watchman Flx, Watchman |
| Abbott Laboratories | $117.66 | 2022-2023 | Amplatzer Amulet, Aveir |
| Novo Nordisk INC | $105.85 | 2024-2025 | Wegovy, Ozempic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $98.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.35 | 2023-2024 | Jardiance |
| Atricure, INC. | $65.60 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $64.95 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $63.88 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $27.65 | 2025 | |
| Esperion Therapeutics, INC. | $26.43 | 2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $25.82 | 2025 | Opsynvi |
| Cardiva Medical, INC. | $23.68 | 2024 | Optowire |
| Philips North America LLC | $21.63 | 2024 | (5091) Amb Mon & Diag Und |
| Lundbeck LLC | $21.48 | 2019 | |
| Merck Sharp & Dohme LLC | $21.42 | 2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $21.33 | 2024 | Evkeeza |
| Astellas Pharma US INC | $15.15 | 2019 | |
| Biotronik INC. | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitika Maddula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.